A nticoagulation is the cornerstone of acute venous thromboembolism (VTE) management. Nonetheless, the use of inferior vena cava (IVC) lters in addition to anticoagulation is increasing, with wide variation in practice patterns and a growing recognition of lter-related complications. Rigorous randomized controlled data demonstrating that IVC lters, particularly the increasingly commonly placed retrievable lters, provide a mortality bene t are sparse. Given our review of IVC lter use and the lack of evidence demonstrating that IVC lters provide a mortality bene t, we recommend using anticoagulation alone for stable medical service patients admitted with acute VTE. In nuanced cases, hospitalists should engage in multidisciplinary care to develop individualized treatment options.
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CASE PRESENTATION
A 65-year-old woman with a history of diabetes mellitus, metastatic breast cancer, and peptic ulcer disease presents to the Emergency Department for the evaluation of right thigh swelling, chest pain, and dyspnea after a transcontinental ight. Physical examination is notable for a pulse of 114 beats per minute, blood pressure of 136/93 mm Hg, respiratory rate of 14 breaths per minute, oxygen saturation of 95% on room air, and swelling of the right thigh. Computerized tomography imaging demonstrates multiple bilateral pulmonary emboli. Emergency department physicians begin anticoagulation and inform you that they have ordered the placement of a retrievable inferior vena cava (IVC) lter.
BACKGROUND
Acute venous thromboembolism (VTE) accounts for more than 500,000 hospitalizations in the United States each year.
1 Although the management of VTE centers around anticoagulation, the concurrent use of IVC lters has increased over the past several decades. 2 Several observational studies have attempted to quantify IVC lter usage and have shown that overall lter placement has increased at an impressive rate. Within two decades, the number of patients undergoing IVC lter placement has increased nearly 25 times from 2,000 in 1979 to 49,000 in 1999.
2 Recent Medicare data show that claims for IVC lter placement procedures have increased from 30,756 in 1999 to 65,041 in 2008.
3 IVC lter placement rates are higher in the US than in other developed countries; one review projected that in 2012, the IVC lter placement rate in a given population in the US is 25 times higher than that in a similar population in Europe. 4 The guidelines for IVC lter usage are largely based on expert opinion, and solid data regarding this intervention are lacking. This combination is problematic, especially because the practice is becoming commonplace, and lter-related complications are increasingly recognized. Additionally, the appropriateness of lter use varies among providers, as evidenced by a retrospective study in which three VTE experts reviewed medical records to determine the appropriateness of lter placement. They unanimously agreed that lter use was appropriate in 51% of the cases, unanimously agreed that lter use was inappropriate in 26% of the cases, and lacked consensus on the appropriateness of lter use in 23% of the cases. 5 The striking lack of consensus among experts underscores the wide range of opinion regarding the appropriateness of IVC lter placement on a case-by-case basis. Moreover, evidence suggests that physician adherence to guidelines for appropriate IVC lter use is suboptimal. One single-center study showed that only 43.5% of lters placed by interventional radiology practitioners met the guidelines established by the American College of Chest Physicians (ACCP), with a slightly increased percentage of lter placement meeting guidelines if the requesting provider is an IM-trained physician. 6 
WHY YOU MIGHT THINK IVC FILTER PLACEMENT IS HELPFUL IN PATIENTS WITH VTE WITHOUT CONTRAINDICATION TO ANTICOAGULATION
In theory, the concept of IVC lters makes intuitive senselters block the ascent of any thrombus from the lower extremities to prevent the feared complication of a pulmonary embolism (PE). Unfortunately, rigorous data are limited, and consensus guidelines vary between different specialty organizations, further obfuscating the role of IVC lter placement in the management of VTE. For example, the ACCP recommends against the use of IVC lters in most patients with VTE receiving anticoagulation and does not list any prophylactic indications. 7, 8 Meanwhile, the Society of Interventional Radiology lists prophylactic indications for IVC lter placement in certain patient populations, such patients with a risk of VTE and a high risk of bleeding, and notes numerous relative indications for IVC lter placement. 8 Notably, these differences in expert opinion likely in uence practice patterns, as evidenced by the increase in IVC lter placement for relative indications. 
WHY IVC FILTERS PLACEMENT IN PATIENTS WITH VTE WHO CAN BE ANTICOAGULATED IS NOT HELPFUL
The Prevention du Risque d'Embolie Pulmonaire par Interruption Cave (PRECIP) trial is the most robust study supporting the 2016 ACCP recommendation against IVC lter use in patients that can receive anticoagulation. 7, 11 This study randomized 400 patients with deep vein thrombosis (DVT) at high risk for PE to anticoagulation with or without permanent lter placement to address VTE and mortality rates associated with IVC lter placement. The trial showed that the VTE burden shifts in the presence of IVC lters. At 2-year follow-up, the group with IVC lters had nonsigni cantly fewer PEs than the control group and an increased incidence of DVT. Mortality rates did not differ between groups. 11 At eight-year follow-up this shift in VTE burden is again seen given that the number of PEs in patients who received IVC lters decreased and the incidence of DVTs increased. Again, mortality did not differ between groups. 12 A subsequent study randomized 399 patients with DVT and acute symptomatic PE with at least one additional marker of severity to anticoagulation with or without retrievable IVC lter placement and showed no difference in recurrent PE or mortality at 3 or 6 months. 13 These results argue against placing retrievable lters in patients receiving anticoagulation.
The identi cation of associated adverse events further favor the judicious use of IVC lters. A retrospective review of the long-term complications of IVC lters based on imaging data showed a 14% fracture rate, 13% IVC thrombosis rate, and a 48% perforation rate.
14 Multiple studies have shown that the associated complication rates of retrievable lters are higher than those of permanent lters; such an association is concerning given that retrievable lter usage exceeds permanent lter usage. 14, 15 The increase in retrievable lter usage is likely attributable to their attractive risk-bene t calculation. In theory, retrievable IVC lters should be perfect for patients who have conditions that increase VTE risk but create temporary contraindications, such as trauma or major surgery, to anticoagulation. However, anticoagulation is preferred over IVC lters in the long term because the complication rates of IVC lters increase with dwell time. 16 Given the reports of adverse events and concern that IVC lters are not appropriately removed, the Food and Drug Administration recommends removing retrievable IVC lters once the risk of lters outweighs the bene ts, which appears to be 29-54 days after implantation. 17 However, successful retrieval rates are low, both because of the low rates of removal attempts and because of the interference of complications, such as embedded or thrombosed lters, with removal. 10, 18 As an example, in a retrospective review of all patients who received an IVC lter at an academic medical center over the period of 2003-2011, nearly 25% of patients were discharged on anticoagulation after IVC lter placement. 10 This suggests that their contraindication to anticoagulation and need for IVC placement have passed by the time of discharge. Nevertheless, clinicians attempted lter retrieval in only 9.6% of these patients, representing a signi cant missed opportunity of treatment with anticoagulation rather than IVC lters. 10 Factors such as lter plan documentation, hematology involvement, patient age ≤70 years, and establishment of dedicated IVC lter clinics are correlated with improved rates of lter removal; these correlations emphasize the importance of a clear follow-up plan in the timely removal of these devices. 18, 19 
WHEN MIGHT IT BE HELPFUL TO PLACE IVC FILTERS IN PATIENTS WITH NO CONTRA-INDICATION TO ANTICOAGULATION?
IVC lter placement is inappropriate in the vast majority of patients with VTE who can be anticoagulated. However the ACCP does acknowledge that a small subset of patientsspeci cally, those with severe or massive PE -may fall outside this guideline. 7 Clinicians fear that these patients have low cardiopulmonary reserve and may experience hemodynamic collapse and death with another "hit" from a recurrent PE. This recommendation is consistent with the evidence that in unstable patients with PE, IVC lter placement is associated with decreased in-hospital mortality. 20 Data remain limited for this situation, and the decision to place an IVC lter in anticoagulated but unstable patients is an individualized one.
WHAT YOU SHOULD DO INSTEAD: REFRAIN FROM IVC FILTER PLACEMENT AND TREAT WITH SYSTEMIC ANTICOAGULATION
In stable patients admitted to the medical service with VTE and who can be anticoagulated, there is little evidence that placement of an IVC lter will improve short-or long-term mortality. Hospitalists should anticoagulate these patients with a vitamin-K antagonist, heparin product, or novel oral anticoagulants.
RECOMMENDATIONS
• Anticoagulate hemodynamically stable patients who are admitted to the medical service with VTE and who do not have a contraindication to anticoagulation. Do not place a permanent or retrievable IVC lter.
• IVC lter placement may bene t unstable patients who may experience hemodynamic collapse with an increased PE burden. IVC lter placement should be discussed with a multidisciplinary team.
• When discharging a patient with an IVC lter, hospitalists should improve retrieval rates by scheduling subsequent re-moval. The discharge summary should contain information about the IVC lter, as well as clear instructions regarding the plan for removal. The instructions should include radiology follow-up information and the designation of responsible physicians in case of questions.
CONCLUSION
Although IVC lter use is increasing, the evidence does not support their use in hemodynamically stable patients who can be anticoagulated. The patient described in the initial case has no contraindication to systemic anticoagulation. Therefore, she should be started on anticoagulation, and an IVC lter should not be placed. 
